Study details
Enrolling now
A Single-Arm Phase II Trial of Aspirin to Prevent Blood Clots in Patients with Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT IDNCT06866964ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
35
Study length
about 5.4 years
Ages
18–70
Locations
3 sites in NC, WI
What this study is about
This trial is testing whether low-dose aspirin can help prevent blood clots (VTE) in adults with advanced germ cell tumors who are receiving chemotherapy. The goal is to compare the 6-month VTE-free rate of participants taking aspirin to historical data from patients without aspirin.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Low-dose ASA
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Overall Survival (OS), Relapse-Free Survival (RFS)
Body systems
Oncology